Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

← catalyst calendar

NCT07590934 · readout in 1,132 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

152estimated

Sites

Countries

Australia, Germany, Italy +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-03

actual

When the study began enrolling

Primary completion

2029-09-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-09-25

estimated

The whole study's end, after follow-up

First posted

2026-05-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Prostate Cancer

Interventions

Drug: AZD2265 (FPI-2265) — also filed as FPI-2265, 225Ac-PSMA-I&T
Drug: AZD9574
Drug: Docetaxel
Drug: AZD2287 (Imaging agent)

Primary outcomes

what the primary-completion date above is the date OF

Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)

measured Up to approximately 1 year after last dose

Part A: Number of participants with dose limiting toxicities (DLTs)

measured From date of first dose up to approximately 2 cycles (up to 3 months)

Part B: Number of participants with TEAEs

measured Up to approximately 1 year after last dose

Part B: Prostate Specific Antigen 50 (PSA50) response rate

measured Up to 3 years 4 months

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed